> Details

Attisano, Tiziana; Silverio, Angelo; Stabile, Eugenio; Briguori, Carlo; Tuccillo, Bernardino; Scotto Di Uccio, Fortunato; Di Lorenzo, Emilio; Tesorio, Tullio; Giordano, Arturo; Calabrò, Paolo; Cappelli Bigazzi, Maurizio; Golino, Paolo; Scherillo, Marino; Vigorito, Francesco; Quaranta, Gaetano; Esposito, Giovanni; Mauro, Ciro; Musumeci, Giuseppe; Tarantini, Giuseppe; Galasso, Gennaro

Safety and feasibility of balloon aortic valvuloplasty in non‐TAVI centers: The “BAV for life” experience

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Safety and feasibility of balloon aortic valvuloplasty in non‐TAVI centers: The “BAV for life” experience
  • Contributor: Attisano, Tiziana; Silverio, Angelo; Stabile, Eugenio; Briguori, Carlo; Tuccillo, Bernardino; Scotto Di Uccio, Fortunato; Di Lorenzo, Emilio; Tesorio, Tullio; Giordano, Arturo; Calabrò, Paolo; Cappelli Bigazzi, Maurizio; Golino, Paolo; Scherillo, Marino; Vigorito, Francesco; Quaranta, Gaetano; Esposito, Giovanni; Mauro, Ciro; Musumeci, Giuseppe; Tarantini, Giuseppe; Galasso, Gennaro
  • Published: Wiley, 2019
  • Published in: Catheterization and Cardiovascular Interventions, 93 (2019) 1
  • Language: English
  • DOI: 10.1002/ccd.27820
  • ISSN: 1522-1946; 1522-726X
  • Origination:
  • Footnote:
  • Description: AbstractObjectivesTo evaluate the safety and the feasibility of balloon aortic valvuloplasty (BAV) procedure made by trained operators in centers not performing transcatheter aortic valve implantation (TAVI).BackgroundBAV is a valuable therapeutic tool for patients with symptomatic severe aortic valve stenosis (AS) at prohibitive risk for TAVI or surgery.MethodsConsecutive high‐risk AS patients underwent BAV in five non‐TAVI centers, where BAV operators had completed a 6‐month training period in high‐volume TAVI centers (Group A). All clinical, echocardiographic, and procedural data were prospectively collected and compared with data of patients treated in TAVI center (Group B).ResultsBetween June 2016 and June 2017, 55 patients (83.9 ± 7.0 years) were enrolled: 25 in Group A and 30 in Group B. After BAV, a substantial reduction of the peak‐to‐peak aortic valve gradient was obtained in both groups (−35.3 ± 15.2 vs −28.8 ± 13.9 mmHg, P =0.25). No major bleeding or vascular complications occurred. In‐hospital death was observed in three patients of Group A and two patients of Group B (P =0.493). The mean follow‐up time was 303 ± 188 days; no patients were lost. The 1‐year survival free from overall death (Group A 75.8% vs Group B 68.8%; P =0.682) and heart failure rehospitalization (Group A 73.0% vs Group B 66.8%; P =0.687) was similar in the two groups. At multivariable analysis, low left ventricular (LV) ejection fraction (HR: 0.943; P = 0.011) and cardiogenic shock (HR: 5.128; P = 0.002) at admission were independent predictors of mortality.ConclusionsBAV is a safe and effective procedure that can be performed by trained operators in centers not performing TAVI.